Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-07-13

Clinical Trial Results: Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating rilzabrutinib in adults with moderate-to-severe atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2026-07-13